NASDAQ:IDRA - Idera Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$0.86 -0.01 (-1.15 %)
(As of 07/23/2018 03:50 AM ET)
Previous Close$0.86
Today's Range$0.83 - $0.8890
52-Week Range$0.80 - $2.87
Volume1.49 million shs
Average Volume2.24 million shs
Market Capitalization$186.89 million
P/E Ratio-2.05
Dividend YieldN/A
Beta2.42
Idera Pharmaceuticals logoIdera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of oligonucleotide therapeutics for oncology and rare diseases in the United States. The company uses two drug discovery technology platforms to design and develop drug candidates, including toll-like receptor targeting technology and nucleic acid chemistry technology. Its drug candidates include IMO-2125, an agonist that is in Phase III clinical trial in combination with ipilimumab and pembrolizumab for the treatment of anti-PD-1 refractory metastatic melanoma; and which is in Phase Ib monotherapy trial in multiple tumor types for the treatment of refractory solid tumors, as well as IMO-8400, an antagonist, which is in Phase II clinical trial for the treatment of dermatomyositis. The company is also developing IDRA-008 apolipoprotein C-III gene target for the treatment of familial chylomicronemia syndrome and familial partial lipodystrophy; nucleic acid chemistry compound for renal target; and IMO-9200 for treating non-malignant gastrointestinal disorders. In addition, it is developing drug candidates to turn off the messenger RNA associated with disease causing genes. Idera Pharmaceuticals, Inc. has collaboration and license agreement with GlaxoSmithKline Intellectual Property Development Limited to license, research, develop, and commercialize pharmaceutical compounds from its nucleic acid chemistry technology for the treatment of selected targets in renal disease; Abbott Molecular Inc. for the development of an in vitro companion diagnostic; and Merck & Co to research, develop, and commercialize vaccine products. The company was founded in 1989 and is based in Cambridge, Massachusetts.

Receive IDRA News and Ratings via Email

Sign-up to receive the latest news and ratings for IDRA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:IDRA
CUSIPN/A
Phone617-679-5500

Debt

Debt-to-Equity RatioN/A
Current Ratio8.89
Quick Ratio8.89

Price-To-Earnings

Trailing P/E Ratio-2.05
Forward P/E Ratio-2.15
P/E GrowthN/A

Sales & Book Value

Annual Sales$900,000.00
Price / Sales207.65
Cash FlowN/A
Price / CashN/A
Book Value$0.55 per share
Price / Book1.56

Profitability

EPS (Most Recent Fiscal Year)($0.42)
Net Income$-65,980,000.00
Net Margins-9,117.07%
Return on Equity-82.70%
Return on Assets-73.93%

Miscellaneous

Employees62
Outstanding Shares217,310,000
Market Cap$186.89

Idera Pharmaceuticals (NASDAQ:IDRA) Frequently Asked Questions

What is Idera Pharmaceuticals' stock symbol?

Idera Pharmaceuticals trades on the NASDAQ under the ticker symbol "IDRA."

How were Idera Pharmaceuticals' earnings last quarter?

Idera Pharmaceuticals Inc (NASDAQ:IDRA) announced its quarterly earnings data on Wednesday, May, 9th. The biotechnology company reported ($0.10) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.09) by $0.01. The biotechnology company earned $0.26 million during the quarter, compared to the consensus estimate of $0.17 million. Idera Pharmaceuticals had a negative net margin of 9,117.07% and a negative return on equity of 82.70%. View Idera Pharmaceuticals' Earnings History.

What price target have analysts set for IDRA?

5 equities research analysts have issued 1 year price targets for Idera Pharmaceuticals' shares. Their forecasts range from $3.00 to $4.00. On average, they anticipate Idera Pharmaceuticals' share price to reach $3.80 in the next year. This suggests a possible upside of 341.9% from the stock's current price. View Analyst Ratings for Idera Pharmaceuticals.

What is the consensus analysts' recommendation for Idera Pharmaceuticals?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Idera Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Who are some of Idera Pharmaceuticals' key competitors?

Who are Idera Pharmaceuticals' key executives?

Idera Pharmaceuticals' management team includes the folowing people:
  • Mr. Vincent J. Milano, Pres, CEO & Director (Age 54)
  • Mr. Louis J. Arcudi III, MBA, Sr. VP of Operations, CFO, Treasurer & Assistant Sec. (Age 57)
  • Dr. Jonathan Yingling, Sr. VP of Early Devel. & Chief Scientific Officer (Age 49)
  • Mr. Robert Clayton Fletcher, Sr. VP of Bus. Devel. & Strategic Planning (Age 55)
  • Dr. Joanna C. Horobin, Sr. VP & Chief Medical Officer (Age 63)

Has Idera Pharmaceuticals been receiving favorable news coverage?

Media headlines about IDRA stock have trended positive on Monday, Accern reports. The research firm ranks the sentiment of press coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Idera Pharmaceuticals earned a media sentiment score of 0.35 on Accern's scale. They also assigned news headlines about the biotechnology company an impact score of 45.33 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next few days.

Who are Idera Pharmaceuticals' major shareholders?

Idera Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Berson & Corrado Investment Advisors LLC (0.05%). Company insiders that own Idera Pharmaceuticals stock include Bros Advisors Lp Baker, Invest Corp Pillar, Julian Baker and Maxine Gowen. View Institutional Ownership Trends for Idera Pharmaceuticals.

Which major investors are buying Idera Pharmaceuticals stock?

IDRA stock was acquired by a variety of institutional investors in the last quarter, including Berson & Corrado Investment Advisors LLC. Company insiders that have bought Idera Pharmaceuticals stock in the last two years include Bros Advisors Lp Baker, Julian Baker and Maxine Gowen. View Insider Buying and Selling for Idera Pharmaceuticals.

How do I buy shares of Idera Pharmaceuticals?

Shares of IDRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Idera Pharmaceuticals' stock price today?

One share of IDRA stock can currently be purchased for approximately $0.86.

How big of a company is Idera Pharmaceuticals?

Idera Pharmaceuticals has a market capitalization of $186.89 million and generates $900,000.00 in revenue each year. The biotechnology company earns $-65,980,000.00 in net income (profit) each year or ($0.42) on an earnings per share basis. Idera Pharmaceuticals employs 62 workers across the globe.

How can I contact Idera Pharmaceuticals?

Idera Pharmaceuticals' mailing address is 167 SIDNEY STREET, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 617-679-5500 or via email at [email protected]


MarketBeat Community Rating for Idera Pharmaceuticals (NASDAQ IDRA)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  246 (Vote Outperform)
Underperform Votes:  159 (Vote Underperform)
Total Votes:  405
MarketBeat's community ratings are surveys of what our community members think about Idera Pharmaceuticals and other stocks. Vote "Outperform" if you believe IDRA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IDRA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.